ERBB2 and breast cancer: A combination of the analysis of Bcl-2 expression and perhaps other variables (e.g., HER-2, hormone receptor, tumor size and histological subtype) may make it possible, to stratify chemotherapy sensitive subgroup of patients with advanced breast cancer.